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oroquinolones is alarming and has grown to be a cause for signiﬁcant concern
worldwide. We report the ﬁrst three cases of levoﬂoxacin resistant S. pneumoniae
isolates in a tertiary medical center in Beirut, Lebanon. Judicious use of antimicro-
bial agents is imperative to limit the spread of such resistant strains.
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ackground
treptococcus pneumoniae remains a predomi-
ant identiﬁable bacterial pathogen in community
cquired pneumonia (CAP) and is associated with
igniﬁcant morbidity and mortality [1,2]. Treatment
uccess has been limited by the increasing preva-
ence of antimicrobial resistance [1,2]. Current
AP-inpatient management guidelines of the Infec-
ious Diseases Society of America (IDSA) and the
merican Thoracic Society (ATS), include respira-
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oi:10.1016/j.jiph.2010.07.003ory ﬂuoroquinolones (FQ), as one of the treatment
ptions [3].
Although the emergence of S. pneumoniae
trains that are resistant to -lactams, macrolides,
nd other antibiotics including FQ, have been
eported from several countries around the world,
evels of resistance to the latter remain low [1].
n 2002, The Centers for Disease Control and Pre-
ention (CDC) estimated that of 37,000 cases of
nvasive disease due to S. pneumoniae, 34% were
esistant to at least one antibiotic, while 17% were
esistant to three or more antibiotics [4,5]. How-
ver, S. pneumoniae has remained, for the most
art, highly susceptible to FQ. Annual surveillance
ata from the US and Italy have shown that S.
Sciences. Published by Elsevier Ltd. All rights reserved.
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pneumoniae resistance to respiratory FQ, includ-
ing levoﬂoxacin and moxiﬂoxacin, were less than
1—3% with minimal yearly increase [5,6]. Further-
more, S. pneumoniae levoﬂoxacin resistance rates
have been reported to be less than 1% in the United
States in 2005—2006 (0.6% resistance and 0.2%
intermediate resistance) [3]. On the other hand,
during 2000—2001, Turkey reported a rise in resis-
tance rates to FQ among invasive S. pneumoniae
reaching up to 3.5% of isolates [1].
In Lebanon, S. pneumoniae isolates have shown
increasing resistance to penicillin, macrolides, and
other antimicrobial agents, but to our knowledge,
none so far have been reported against FQ [2,7,8].
This is consistent with data published from other
countries in the Middle East, including Saudi Arabia
and Qatar [9,10]. However, in September 2006 we
identiﬁed the ﬁrst levoﬂoxacin resistant S. pneu-
moniae at our institution. Since then, and over the
past 5 years, a total of three cases of FQ resistant S.
pneumoniae have been identiﬁed, warranting their
documentation.
Methods
Isolates of S. pneumoniae were obtained from
fresh clinical samples taken from the concerned
three patients with clinical evidence of respiratory
tract infections using routine collection methods.
Minimum inhibitory concentrations (MICs) of the
isolates were determined by E-test susceptibility
testing method according to the manufacturer’s
instructions (AB, Biodisk, Solna, Sweden). Disc
diffusion susceptibility testing was performed
against a range of antimicrobial agents accord-
ing to the Clinical and Laboratory Standards
Institute (CLSI) interpretive guidelines. Also the
CLSI breakpoint MICs (g/ml) for S. pneumoniae
against penicillin was used as follows: susceptible
(≤2), intermediate (4), resistant (≥8) for par-
enteral (non-meningitis); and susceptible (≤0.06),
intermediate (0.12—1), resistant (≥2) for oral for-
mulations.
Patient A
A 78-year-old male with a history of chronic
obstructive pulmonary disease (COPD) and chronic
lymphocytic leukemia was admitted to the Amer-
ican University of Beirut Medical Center (AUBMC)
with fever, productive cough, and dyspnea. He
had been treated as out-patient in another hos-
pital, with numerous courses of oral levoﬂoxacin
and ciproﬂoxacin of undocumented doses, for
p
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(M.R. Naba et al.
ecurrent lower respiratory tract infections,
he last of which being 10 days prior to his
urrent presentation. Findings upon admission
ncluded: a blood pressure of 115/88mmHg,
emperature of 40 ◦C, pulse of 128min−1 and a
espiratory rate of 35min−1. Chest auscultation
evealed decreased breath sounds with diffuse
honchi. Laboratory data showed a white cell
ount of 75,000 cells/mm3 with 94% lympho-
ytes, and a creatinine of 1.5mg/dl. CT-scan of
he chest showed bilateral consolidations. The
atient was started empirically on intravenous
efepime (2 g every 8 h) and oral clarithromycin
500mg tablets twice daily) after blood and spu-
um cultures were taken. Subsequently, blood
ultures grew S. pneumoniae which showed inter-
ediate resistance to penicillin based on oral
SLI breakpoint guidelines (MIC = 0.5g/ml) and
as resistant to levoﬂoxacin (MIC > 32g/ml),
ut susceptible to clindamycin, erythromycin,
eftriaxone (MIC = 0.38g/ml) and trimetho-
rim/sulfamethoxazole. The patient improved
fter 72 h of initiating therapy and the same
ntibiotic regimen was continued for 10 days with
o complications.
atient B
66-year-old male with multiple co-morbidities,
resented to AUBMC with cough and dyspnea.
he patient had a history of recurrent aspiration
neumonia and had received multiple courses
f oral levoﬂoxacin and amoxicillin/clavulanate.
is most recent hospitalization with pneumonia
as 3 weeks prior to the current presenta-
ion, at which time he received intravenous
iperacillin/tazobactam (4.5 g every 8 h) and was
ater discharged on oral amoxicillin/clavulanate
1 g tablets twice daily). Physical examination
howed: a temperature of 37 ◦C, blood pressure
f 120/80mmHg, pulse of 88min−1 and a respi-
atory rate of 30min−1, with bilateral decreased
reath sounds on lung auscultation. His white cell
ount was 11,700 cell/mm3, with 77% neutrophils
nd his creatinine was 0.3mg/dl. A CT-scan of
he chest showed left lobe consolidation and a
ediastinal mass. Blood and sputum cultures
ere taken and the patient was given intra-
enous amoxicillin/clavulanate (1.2 g every 8 h).
ubsequently, sputum culture grew extended spec-
rum beta-lactamase (ESBL) producing Klebsiella
neumoniae, and a multidrug-resistant (MDR) S.
neumoniae with the following susceptibility pro-
le: fully resistant to penicillin based on oral CSLI
reakpoint guidelines (MIC = 3g/ml), ceftriaxone
MIC = 2g/ml), levoﬂoxacin (MIC > 32g/ml),
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lindamycin, erythromycin, tetracycline, and
rimethoprim/sulfamethoxazole, but suscepti-
le to rifampin, vancomycin, and teicoplanin.
espite negative blood cultures, the patient
as treated with intravenous vancomycin (1 g
very 12 h) and imipenem (500mg every 6 h)
or a clinical picture that was consistent with
neumonia and showed marked improvement.
e was soon after diagnosed to have poorly
ifferentiated lung carcinoma, followed by a
omplicated hospital course, and died 3 months
ater.
atient C
78-year-old male admitted to AUBMC with a
ecent history of watery diarrhea, with no associ-
ted abdominal pain, nausea, nor fever. The patient
ad a history of cellulitis, treated with antibiotics
months earlier, and non-small cell lung cancer,
or which he received radiotherapy and chemother-
py. On admission he reported dyspnea and a
roductive cough with blood tinged sputum. Find-
ngs included: a blood pressure of 130/70mmHg,
emperature of 36.6 ◦C, pulse of 85min−1 and a
espiratory rate of 16min−1. When examined, the
atient had decreased breath sounds on ausculta-
ion. Laboratory data showed a white cell count
f 6100 cells/mm3 with 89% neutrophils. His cre-
tinine value was 0.5mg/dl and his O2 saturation
1% on room air. Chest X-ray revealed new inﬁl-
rates in the right lobe. Therapy was initiated with
ral rifaximin (400mg tablets every 12 h) and mox-
ﬂoxacin (400mg every 24 h). Subsequently, stool
ultures grew Salmonella spp. group C resistant to
uinolones and susceptible to cephalosporins and
rimethoprim/sulfamethoxazole (TMP/SMX). Fur-
hermore, the patient had a drop of his absolute
eutrophil count to 220. Thus, treatment was
hifted to cefdinir (300mg every 12 h).
During his hospitalization, the patient under-
ent bronchoscopy, and was found to have an
ndobronchial mass. BAL cultures taken during
he procedure grew Stenotrophomonas maltophilia
nd S. pneumoniae which was fully resistant to
enicillin based on oral CSLI breakpoint guide-
ines (MIC = 2g/ml), levoﬂoxacin (MIC > 32g/ml)
nd TMP/SMX, but susceptible to ceftriaxone
MIC = 1g/ml), vancomycin, teicoplanin and tetra-
ycline. The patient was started on intravenous
eftazidime (2 g every 8 h) and vancomycin (1 g
very 12 h) with no clinical improvement and thus
as shifted to intravenous ceftriaxone (2 g every
4 h) and TMP/SMX double strength every 12 h.
espite efforts, the patient clinically deteriorated
nd died 21 days after hospitalization.
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iscussion
ue to the time required to establish the iden-
ity and susceptibility of bacterial pathogens
rom patients with CAP, therapeutic choices are
requently empirical. There is increasing evi-
ence that inappropriate empirical therapy results
n increased rates of morbidity and mortality
mong patients with serious bacterial infections
11]. Therefore, in immunocompromised patients,
atients with a history of FQ therapy in the past
—4 months, and in patients with other risk fac-
ors for FQ resistance, it may not be prudent to use
Q monotherapy empirically to treat suspected or
roven pneumococcal infection until susceptibility
ata become available [12]. To evaluate the con-
istency of medical management at our institution
ith IDSA guidelines for CAP, a study enrolled a total
f 65 adult patients diagnosed with CAP between
ecember 2000 and May 2001 [13]. It was found
hat all 65 patients had received empirical ther-
py, with levoﬂoxacin being the most commonly
rescribed monotherapy (51%). Although generally
dministered in the recommended doses, 12 of 22
atients received an inappropriate dosage of lev-
ﬂoxacin (500mg twice daily). The authors argue
hat, while the overall medical practice was con-
istent with IDSA CAP guidelines; the majority of
atients treated with levoﬂoxacin were classiﬁed
s low risk according to the Pneumonia Patient
utcomes Research Team (PORT) criteria, and thus
ould have been managed with alternative antimi-
robials to avoid losing the FQ efﬁcacy to resistance
13,14].
Although low incidences have been reported
rom the USA, there have been reports of an alarm-
ng increase in resistance to FQ in S. pneumoniae
rom different parts of the world with rates rang-
ng from 5.3% in Spain, 12.1% in Hong Kong, to 15.2%
n Ireland [15]. In Lebanon, and up to this current
eport, no FQ S. pneumoniae resistant isolates have
een reported, although the ﬁrst penicillin resistant
train was reported in 1996 [2,7,8]. Based on disc
iffusion testing, an annually circulated brochure
n antimicrobial susceptibility patterns of bacte-
ial isolates collected at AUBMC since 2006 show
enicillin resistant S. pneumoniae strains to range
rom 64 to 72%. MIC data from the latter have
hown the fully penicillin resistant strains to range
etween 12% and 15% (based on oral penicillin CLSI
IC breakpoints). (AUBMC, Clinical Microbiology,
epartment of Pathology and Laboratory Medicine,
npublished data).
Resistance is a stepwise process, and is deter-
ined by efﬂux mechanisms and/or mutations
n the quinolone resistance-determining regions
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(QRDRs) of parC and parE genes coding for topoi-
somerase IV, and/or gyrA and gyrB genes coding
for DNA gyrase [16]. Although not studied in our
isolates, due to the retrospective nature of our
data collection, the molecular basis of resistance in
S. pneumoniae worldwide is a combined mutation
of both gyrA and parC genes [16,17]. For exam-
ple, among 1817 screened S. pneumoniae isolates
in 44 US hospitals, 21% of the isolates were found
to have mutations in the QRDRs of parC and/or
gyrA that resulted in diminished quinolone activ-
ity [17]. Isolates with more than one mutation
become resistant to older quinolones but remain
susceptible to the newer members of the quinolone
class [18]. Therefore, assessment of the frequency
with which resistance mutations take place, may
represent a reﬁned means for tracking changes
in FQ resistance patterns [15]. The proportion of
resistant isolates are encountered more frequently
among older subjects and patients with chronic
lung disease [15]. A prospective cohort study of
3339 patients with invasive pneumococcal infection
between 1995 and 2002 showed that previous FQ
use (odds ratio [OR] = 12.1), current residence in a
nursing home (OR = 12.9), and nosocomial acquisi-
tion of infection (OR = 9.9) were all signiﬁcant risk
factors for infection with a FQ resistant S. pneu-
moniae strain [15]. Other risk factors included the
presence of COPD and immunosuppressive condi-
tions [5,19]. All three of our patients had several
of these risk factors.
The emergence of FQ resistant S. pneumoniae in
Lebanon constitutes a serious threat to the treat-
ment of potentially life-threatening pneumococcal
infections. Although our ﬁndings in the presented
cases cannot be generalized and are not neces-
sarily representative of local medical practice,
efﬁcient patient management should be based on
local resistance patterns in selecting proper antimi-
crobial therapy. At this point, further prospective
surveillance studies are crucial in clarifying the
extent of the local patterns of resistance and
in guiding judicious antimicrobial therapy to help
prevent the possible emergence of new resistant
pathogens.
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